Issue Date: May 11, 2015
Inhibitors Make Rare Landing On Longstanding Anticancer Target Ras
Mutated Ras signaling proteins, frequently found in human cancer cells, are like airports with hard-to-find runways. They lack prominent binding sites for small molecules, so prospective anticancer drugs don’t land there very often. None has ever been approved commercially, despite decades of effort.
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society